~~<i id='E8AFFBBA4B'><strike id='E8AFFBBA4B'><tt id='E8AFFBBA4B'><pre id='E8AFFBBA4B'></pre></tt></strike></i>~~

Home» comprehensive» leisure time

leisure time

author：knowledge 2025-10-06 15:06:28 Page View：179

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Large hospital system sues Multiplan for low
Next article： Bright Health sells Medicare Advantage business to Molina

explore

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

White House drug shortages task force keeps mum with Congress

AdobeWASHINGTON—AWhiteHousetaskforcecreatedtoworkondrugshortagereformshasyettocontactthelawmakerswho

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

Pancreatic cancer early detection could be helped by AI

SuzanneKreiter/GlobestaffLimorAppelbaumhasseentoomanypatientswhosefirstsignofafatalillnesscametoolat

WSS

leisure time

leisure time

focus

explore

Pancreatic cancer early detection could be helped by AI